John Crowley, CEO of Novazyme Pharmaceuticals, a start-up biotechnology firm establishing an orphan drug to deal with an uncommon lysosomal storage disorder that his children suffer, must choose from a partnership along with a buyout to possess sufficient funds and support to obtain the drug towards the market. Associated this dilemma are questions relevant to Novazyme's medical trial strategy, marketing, sales, production, and prices. This case introduces students towards the Food and drug administration drug approval process and government-supported financial inducements to build up drugs for small patient populations. Offers understanding of the character of proper associations within the biotechnology and pharmaceutical industries.
Estimated Submission On |